VU Research Portal

Total Page:16

File Type:pdf, Size:1020Kb

VU Research Portal VU Research Portal Behavioral Phenotyping of Complex Traits in Inbred and Mutant Mice Maroteaux, G.P. 2014 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Maroteaux, G. P. (2014). Behavioral Phenotyping of Complex Traits in Inbred and Mutant Mice. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 23. Sep. 2021 BEHAVIORAL PHENOTYPING OF COMPLEX TRAITS IN INBRED AND MUTANT MICE Gregoire Pierre Maroteaux Cover and chapters Artwork: Anton Rammelt Printed by www.offpages.nl ISBN 978-94-6182-464-6 Copyright © G. Maroteaux, 2014 All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission of the author. The printing of this thesis was sponsored by: VRIJE UNIVERSITEIT BEHAVIORAL PHENOTYPING OF COMPLEX TRAITS IN INBRED AND MUTANT MICE ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. F.A. van der Duyn Schouten, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de Faculteit der Aard- en Levenswetenschappen op donderdag 25 september 2014 om 9.45 uur in de aula van de universiteit, De Boelelaan 1105 door Gregoire Pierre Maroteaux geboren te Versailles, Frankrijk promotor: prof.dr. M. Verhage copromotoren: dr. R.O. Stiedl dr. S. van der Sluis leescommissie: prof.dr. J.D. Armstrong prof.dr. B.M. Spruijt prof.dr. A.B. Smit dr. M. Kas dr. T. Pattij TABLE OF CONTENTS Chapter 1 General introduction 11 Behavioral phenotyping 13 Genetically engineered mice: 15 key to human genetic disease mechanisms Importance of the synapse in psychiatric disorders 18 Aim of this thesis 22 Chapter 2 High throughput phenotyping of avoidance 25 learning in mice discriminates different genotypes and identifies a novel gene Introduction 28 Material & methods 29 Results 32 Discussion 40 Supplemental 43 Chapter 3 Heterozygous Munc18-1 mice exhibit an increased 57 anxiety-like phenotype but no cognitive impairment Introduction 60 Material & methods 60 Results 62 Discussion 68 Conclusions 71 Supplemental 72 Chapter 4 Functional characterization of the PCLO S4814A 89 variant associated with major depressive disorder reveals cellular but not behavioral differences Introduction 92 Results 93 Discussion 106 Material & methods 107 Supplemental 114 Chapter 5 Random mutagenesis by transposon-based gene 125 trap insertion in mice identifies a role of Ubn1 in avoidance learning and fear conditioning Introduction 128 Material and methods 129 Results 133 Discussion 139 Supplemental 143 Chapter 6 General discussion 145 General aim 147 Limitations of standalone tests 148 Home cage relevance 149 The validation of new paradigms 152 Limitations of a new paradigm 154 Accuracy of animal models 155 Future directions 156 Final remarks 157 Chapter 7 Material & Methods 159 Laboratory animals 161 The test battery 161 Automated home cage observation and data analyses 169 Statistical analysis 170 References 173 Abbrevations 187 Samenvatting 189 Summary 193 Acknowledgment 195 Chapter General introduction 1 BEHAVIORAL PHENOTYPING In 1839, Darwin described the behavioral phenotype of 12 species of finches of the Galapagos 1 Islands. He demonstrated the correlation between feeding behavior, morphology of the beak, G and the environment of finches (Darwin, 1839) exemplifying the impact of genetic radiation on eneral morphological differences underlying behavioral adaptation even before the understanding of the genetic basis (Mendel, 1865). Behavioral phenotyping is the description and analysis of introduction internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal and/or external stimuli (Levitis et al., 2009). The behavioral response of an organism is a complex process dependent on gene expression, physiology and interaction with the environment. Distinct behavioral deviations from normally observed responses can be predictive signs for neurological pathologies and psychiatric disorders in human. Thus, the understanding of the biological mechanisms involved in those behaviors is essential. The complexity of behavior requires the use of animal models to mimic human neurological and psychiatric diseases. The last decades were marked by the expansion of new technologies in genetics, brain imaging and molecular biology, to increase the precision, the wealth and the reproducibility of newly generated results. However, behavioral phenotyping – due to its complexity – has not yet experienced this revolution and still is hampered by poor reproducibility and low throughput (Crabbe et al., 1999). In this chapter, the reasons for the development of a new approach of behavioral phenotyping are introduced, followed by the relevance of investigating behavior in mice and comparing different genetic backgrounds or targeted mutations as well as in random mutation in different genes. Thereby the focus will be directed towards the importance of presynaptic genes in neurologic and psychiatric disorders. In need of a new behavior approach For decades, scientists strove to develop a variety of appropriate behavioral tests for rodent phenotyping. The most commonly used behavioral tests are based on locomotor activity measures in acute tests of short duration, normally 5 min to less frequently 60 min. Classical examples like anxiety assessment in an open field (OF), an elevated plus maze (EPM), or a dark- light box (DLB) (Crawley and Goodwin, 1980; Hall and L, 1932; Pellow et al., 1985) or learned behavior, such as performance in the Barnes maze task (BM) and the 5-choice serial reaction time task (5-CSRTT) (Barnes, 1979; Robbins, 2002). To describe the effect of a genetic background, a mutation or a drug on behavior, a battery of tests is required to tap into different aspects of behavior such as motor, sensory, cognitive and circadian functions. Such test batteries, like the SHIRPA protocol (Rogers et al., 1997) or IMPReSS protocol (Brown and Moore, 2012; Brown et al., 2005), are designed to cover muscle, cerebellar, sensory and neuropsychiatric functions. Those sets of experimental procedures contain different tests across several screens of increasing complexity and specialization (Nolan et al., 2000). These test batteries have standardized protocols to improve comparability and reproducibility across studies. However, the succession of tests in those batteries requires repeated human-animal interaction. Carry- over effects can be caused by the order in which tests are performed on the same cohort of animals. Moreover, environmental effects, the lack of consistency in the protocols between 13 laboratories, discrepancies in the data collection methods (visual scoring vs. computerized) and operational definition (e.g. definitions of grooming, rearing, lingering) are also sources of variation in the results that lead to different interpretations (Crabbe et al., 1999; Turner and Burne, 2013; Wahlsten et al., 2003; Würbel, 2002). Considering the huge number of variables that directly or indirectly affect behavioral testing, it is no surprise that behavioral testing is a bottleneck in screening for genes involved in neurological disorders and the development of novel drug treatments. Consequently, there is growing consensus that behavioral testing needs a boost toward automation to increase its effectiveness and standardization in the study of animal models of human diseases and therapeutic developments (Crabbe and Morris, 2004; Smith and Eppig, 2012; Tecott and Nestler, 2004). New technology: home cage recording With the development of advanced video-tracking software, computer power and data storage capacity, new behavioral technologies have emerged, allowing automated observation of animals in their home cage over long periods of time (de Visser et al., 2006; Goulding et al., 2008; Jhuang et al., 2010). Automation of observation allows repetitive, objective, and consistent measurement over days or even weeks, rather than minutes or hours. This substantially increases the scientific efficiency with respect to the researcher’s investment of time and effort. Continuous tracking has increased the behavioral throughput and decreased confounding factors like handling, and the frequent adjustment to novel environments that is required in batteries of classical behavioral tests. Furthermore, continuous recording allows investigation of multi-dimensional aspects of behavior like habituation, baseline and challenged behavior (de Mooij-van Malsen et al., 2009; de Visser et al., 2006; Kas et al., 2008), offering the possibility to study longitudinally the progression of
Recommended publications
  • A Novel PAX5 Rearrangement in TCF3
    Barbosa et al. BMC Medical Genomics (2018) 11:122 https://doi.org/10.1186/s12920-018-0444-9 CASE REPORT Open Access A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report Thayana Conceição Barbosa1,2, Bruno Almeida Lopes1, Caroline Barbieri Blunck1, Marcela Braga Mansur1, Adriana Vanessa Santini Deyl3, Mariana Emerenciano1† and Maria S. Pombo-de-Oliveira2*† Abstract Background: Chromosome translocations are a hallmark of B-cell precursor acute lymphoblastic leukemia (BCP- ALL). Additional genomic aberrations are also crucial in both BCP-ALL leukemogenesis and treatment management. Herein, we report the phenotypic and molecular cytogenetic characterization of an extremely rare case of BCP-ALL harboring two concomitant leukemia-associated chromosome translocations: t(1;19)(q23;q13.3) and t(9;17)(p13;q11. 2). Of note, we described a new rearrangement between exon 6 of PAX5 and a 17q11.2 region, where intron 3 of SPECC1 is located. This rearrangement seems to disrupt PAX5 similarly to a PAX5 deletion. Furthermore, a distinct karyotype between diagnosis and relapse samples was observed, disclosing a complex clonal evolution during leukemia progression. Case presentation: A 16-year-old boy was admitted febrile with abdominal and joint pain. At clinical investigation, he presented with anemia, splenomegaly, low white blood cell count and 92% lymphoblast. He was diagnosed with pre-B ALL and treated according to high risk GBTLI-ALL2009. Twelve months after complete remission, he developed a relapse in consequence of a high central nervous system and bone marrow infiltration, and unfortunately died. Conclusions: To our knowledge, this is the first report of a rearrangement between PAX5 and SPECC1.
    [Show full text]
  • Integrative Clinical Sequencing in the Management of Refractory Or
    Supplementary Online Content Mody RJ, Wu Y-M, Lonigro RJ, et al. Integrative Clinical Sequencing in the Management of Children and Young Adults With Refractory or Relapsed CancerJAMA. doi:10.1001/jama.2015.10080. eAppendix. Supplementary appendix This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 SUPPLEMENTARY APPENDIX Use of Integrative Clinical Sequencing in the Management of Pediatric Cancer Patients *#Rajen J. Mody, M.B.B.S, M.S., *Yi-Mi Wu, Ph.D., Robert J. Lonigro, M.S., Xuhong Cao, M.S., Sameek Roychowdhury, M.D., Ph.D., Pankaj Vats, M.S., Kevin M. Frank, M.S., John R. Prensner, M.D., Ph.D., Irfan Asangani, Ph.D., Nallasivam Palanisamy Ph.D. , Raja M. Rabah, M.D., Jonathan R. Dillman, M.D., Laxmi Priya Kunju, M.D., Jessica Everett, M.S., Victoria M. Raymond, M.S., Yu Ning, M.S., Fengyun Su, Ph.D., Rui Wang, M.S., Elena M. Stoffel, M.D., Jeffrey W. Innis, M.D., Ph.D., J. Scott Roberts, Ph.D., Patricia L. Robertson, M.D., Gregory Yanik, M.D., Aghiad Chamdin, M.D., James A. Connelly, M.D., Sung Choi, M.D., Andrew C. Harris, M.D., Carrie Kitko, M.D., Rama Jasty Rao, M.D., John E. Levine, M.D., Valerie P. Castle, M.D., Raymond J. Hutchinson, M.D., Moshe Talpaz, M.D., ^Dan R. Robinson, Ph.D., and ^#Arul M. Chinnaiyan, M.D., Ph.D. CORRESPONDING AUTHOR (S): # Arul M.
    [Show full text]
  • Supplementary Table 1 Double Treatment Vs Single Treatment
    Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19
    [Show full text]
  • Characterization of SPECC1L Function in Cell Adhesion and Migration in Craniofacial Morphogenesis by © 2017 Nathan Wilson B.Sc., Rockhurst University, 2010
    Characterization of SPECC1L function in cell adhesion and migration in craniofacial morphogenesis By © 2017 Nathan Wilson B.Sc., Rockhurst University, 2010 Submitted to the graduate degree program in Anatomy and Cell Biology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dr. Irfan Saadi, Ph.D. (Chair) Dr. András Czirók, Ph.D. Dr. William Kinsey, Ph.D. Dr. Paul Trainor, Ph.D. Dr. Pamela Tran, Ph.D. Dr. Jinxi Wang, M.D., Ph.D. Date Defended: 19 April 2017 The dissertation committee for Nathan Wilson certifies that this is the approved version of the following dissertation: Characterization of SPECC1L function in cell adhesion and migration in craniofacial morphogenesis Dr. Irfan Saadi, Ph.D. (Chair) Date approved: 12 May 2017 ii Abstract Orofacial clefts are frequent congenital malformations, which can result from reduced contribution of cranial neural crest cells (CNCCs) to the developing cranium. Upon delamination from embryonic neural folds, CNCCs migrate to pharyngeal arches, which give rise to mid-facial structures. Previously, mutations in the cytoskeletal gene SPECC1L were implicated in rare, severe atypical facial clefting. Overexpression of a patient isolated SPECC1L mutation showed disrupted association with acetylated microtubules. We show a similar disruption upon overexpression of SPECC1L variants isolated from patients with less severe syndromic cleft lip and palate. Severe Specc1l deficiency in homozygous mouse mutants is embryonic lethal, showing a reduction in pan-AKT levels and arrested CNCC delamination from the neural folds. Staining of adherens junction (AJ) proteins is increased in mutant neural folds, consistent with impaired CNCC delamination, a process requiring AJ dissolution.
    [Show full text]
  • Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors
    MITOTIC CHECKPOINTS AND CHROMOSOME INSTABILITY ARE STRONG PREDICTORS OF CLINICAL OUTCOME IN GASTROINTESTINAL STROMAL TUMORS. Pauline Lagarde1,2, Gaëlle Pérot1, Audrey Kauffmann3, Céline Brulard1, Valérie Dapremont2, Isabelle Hostein2, Agnès Neuville1,2, Agnieszka Wozniak4, Raf Sciot5, Patrick Schöffski4, Alain Aurias1,6, Jean-Michel Coindre1,2,7 Maria Debiec-Rychter8, Frédéric Chibon1,2. Supplemental data NM cases deletion frequency. frequency. deletion NM cases Mand between difference the highest setswith of theprobe a view isdetailed panel Bottom frequently. sorted totheless deleted theprobe are frequently from more and thefrequency deletion represent Yaxes inblue. are cases (NM) metastatic for non- frequencies Corresponding inmetastatic (red). probe (M)cases sets figureSupplementary 1: 100 100 20 40 60 80 20 40 60 80 0 0 chr14 1 chr14 88 chr14 175 chr14 262 chr9 -MTAP 349 chr9 -MTAP 436 523 chr9-CDKN2A 610 Histogram presenting the 2000 more frequently deleted deleted frequently the 2000 more presenting Histogram chr9-CDKN2A 697 chr9-CDKN2A 784 chr9-CDKN2B 871 chr9-CDKN2B 958 chr9-CDKN2B 1045 chr22 1132 chr22 1219 chr22 1306 chr22 1393 1480 1567 M NM 1654 1741 1828 1915 M NM GIST14 GIST2 GIST16 GIST3 GIST19 GIST63 GIST9 GIST38 GIST61 GIST39 GIST56 GIST37 GIST47 GIST58 GIST28 GIST5 GIST17 GIST57 GIST47 GIST58 GIST28 GIST5 GIST17 GIST57 CDKN2A Supplementary figure 2: Chromosome 9 genomic profiles of the 18 metastatic GISTs (upper panel). Deletions and gains are indicated in green and red, respectively; and color intensity is proportional to copy number changes. A detailed view is given (bottom panel) for the 6 cases presenting a homozygous 9p21 deletion targeting CDKN2A locus (dark green).
    [Show full text]
  • A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression
    Supplementary Materials A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression Table S1. Statistically significant DEGs (Adj. p-value < 0.01) derived from meta-analysis for samples irradiated with high doses of HZE particles, collected 6-24 h post-IR not common with any other meta- analysis group. This meta-analysis group consists of 3 DEG lists obtained from DGEA, using a total of 11 control and 11 irradiated samples [Data Series: E-MTAB-5761 and E-MTAB-5754]. Ensembl ID Gene Symbol Gene Description Up-Regulated Genes ↑ (2425) ENSG00000000938 FGR FGR proto-oncogene, Src family tyrosine kinase ENSG00000001036 FUCA2 alpha-L-fucosidase 2 ENSG00000001084 GCLC glutamate-cysteine ligase catalytic subunit ENSG00000001631 KRIT1 KRIT1 ankyrin repeat containing ENSG00000002079 MYH16 myosin heavy chain 16 pseudogene ENSG00000002587 HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 ENSG00000003056 M6PR mannose-6-phosphate receptor, cation dependent ENSG00000004059 ARF5 ADP ribosylation factor 5 ENSG00000004777 ARHGAP33 Rho GTPase activating protein 33 ENSG00000004799 PDK4 pyruvate dehydrogenase kinase 4 ENSG00000004848 ARX aristaless related homeobox ENSG00000005022 SLC25A5 solute carrier family 25 member 5 ENSG00000005108 THSD7A thrombospondin type 1 domain containing 7A ENSG00000005194 CIAPIN1 cytokine induced apoptosis inhibitor 1 ENSG00000005381 MPO myeloperoxidase ENSG00000005486 RHBDD2 rhomboid domain containing 2 ENSG00000005884 ITGA3 integrin subunit alpha 3 ENSG00000006016 CRLF1 cytokine receptor like
    [Show full text]
  • Supplementary Figures S1-S3
    selected-GBID Uni-genename Uni-title p value NM_001299 CNN1 Calponin 1, basic, smooth muscle 0.0174 NM_002836 PTPRA Protein tyrosine phosphatase, receptor type, A 0.0256 NM_003380 VIM Vimentin 0.004 NM_033119 NKD1 Naked cuticle homolog 1 (Drosophila) 0.004 NM_052913 KIAA1913 KIAA1913 0.004 NM_005940 MMP11 Matrix metallopeptidase 11 (stromelysin 3) 0.0069 NM_018032 LUC7L LUC7-like (S. cerevisiae) 0.0367 NM_005269 GLI1 Glioma-associated oncogene homolog 1 (zinc finger protein) 0.0174 BE463997 ARL9 ADP-ribosylation factor-like 9 0.0367 NM_015939 CGI-09 CGI-09 protein 0.0023 NM_002961 S100A4 S100 calcium binding protein A4 (calcium protein, calvasculin, 0.0324 metastasin, murine placental homolog) NM_003014 SFRP4 Secreted frizzled-related protein 4 0.0005 NM_080759 DACH1 Dachshund homolog 1 (Drosophila) 0.004 NM_053042 KIAA1729 KIAA1729 protein 0.004 BX415194 MGC16121 Hypothetical protein MGC16121 0.0367 NM_182734 PLCB1 Phospholipase C, beta 1 (phosphoinositide-specific) 0.0023 NM_006643 SDCCAG3 Serologically defined colon cancer antigen 3 0.011 NM_000088 COL1A1 Collagen, type I, alpha 1 0.0174 NM_033292 CASP1 Caspase 1, apoptosis-related cysteine peptidase 0.0367 (interleukin 1, beta, convertase) NM_003956 CH25H Cholesterol 25-hydroxylase 0.0256 NM_144658 DOCK11 Dedicator of cytokinesis 11 0.011 AK024935 NODATA CDNA: FLJ21283 fis, clone COL01910 0.0363 AL050227 PTGER3 Prostaglandin E receptor 3 (subtype EP3) 0.0367 NM_012383 OSTF1 Osteoclast stimulating factor 1 0.0023 NM_145040 PRKCDBP Protein kinase C, delta binding protein 0.0069 NM_000089
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Novel and Highly Recurrent Chromosomal Alterations in Se´Zary Syndrome
    Research Article Novel and Highly Recurrent Chromosomal Alterations in Se´zary Syndrome Maarten H. Vermeer,1 Remco van Doorn,1 Remco Dijkman,1 Xin Mao,3 Sean Whittaker,3 Pieter C. van Voorst Vader,4 Marie-Jeanne P. Gerritsen,5 Marie-Louise Geerts,6 Sylke Gellrich,7 Ola So¨derberg,8 Karl-Johan Leuchowius,8 Ulf Landegren,8 Jacoba J. Out-Luiting,1 Jeroen Knijnenburg,2 Marije IJszenga,2 Karoly Szuhai,2 Rein Willemze,1 and Cornelis P. Tensen1 Departments of 1Dermatology and 2Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands; 3Department of Dermatology, St Thomas’ Hospital, King’s College, London, United Kingdom; 4Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands; 5Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; 6Department of Dermatology, Gent University Hospital, Gent, Belgium; 7Department of Dermatology, Charite, Berlin, Germany; and 8Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden Abstract Introduction This study was designed to identify highly recurrent genetic Se´zary syndrome (Sz) is an aggressive type of cutaneous T-cell alterations typical of Se´zary syndrome (Sz), an aggressive lymphoma/leukemia of skin-homing, CD4+ memory T cells and is cutaneous T-cell lymphoma/leukemia, possibly revealing characterized by erythroderma, generalized lymphadenopathy, and pathogenetic mechanisms and novel therapeutic targets. the presence of neoplastic T cells (Se´zary cells) in the skin, lymph High-resolution array-based comparative genomic hybridiza- nodes, and peripheral blood (1). Sz has a poor prognosis, with a tion was done on malignant T cells from 20 patients. disease-specific 5-year survival of f24% (1).
    [Show full text]
  • Whole-Exome Sequencing Identified Genetic Risk Factors for Asparaginase-Related Complications in Childhood ALL Patients
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 27), pp: 43752-43767 Research Paper Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients Rachid Abaji1,7, Vincent Gagné1, Chang Jiang Xu1, Jean-François Spinella1, Francesco Ceppi1, Caroline Laverdière1,2, Jean-Marie Leclerc1,2, Stephen E. Sallan3,4, Donna Neuberg5, Jeffery L. Kutok6, Lewis B. Silverman3,4, Daniel Sinnett1,2 and Maja Krajinovic1,2,7 1 Research Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada 2 Department of Pediatrics, University of Montreal, Montreal, QC, Canada 3 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 4 Division of Hematology/Oncology, Children’s Hospital, Boston, MA, USA 5 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA 6 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA 7 Department of Pharmacology, University of Montreal, Montreal, QC, Canada Correspondence to: Maja Krajinovic, email: [email protected] Keywords: acute lymphoblastic leukemia; asparaginase; exome-wide association; pharmacogenetics; whole-exome sequencing Received: April 21, 2017 Accepted: April 27, 2017 Published: May 17, 2017 Copyright: Abaji et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Allergy, pancreatitis and thrombosis are common side-effects of childhood acute lymphoblastic leukemia (ALL) treatment that are associated with the use of asparaginase (ASNase), a key component in most ALL treatment protocols.
    [Show full text]
  • Comparative Genomic Analysis of Rapidly Evolving SARS-Cov-2 Viruses 2 Reveal Mosaic Pattern of Phylogeographical Distribution
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.006213; this version posted April 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Viruses 2 Reveal Mosaic Pattern of Phylogeographical Distribution 3 Roshan Kumar1, Helianthous Verma2, Nirjara Singhvi3, Utkarsh Sood4, Vipin Gupta5, Mona 4 Singh5, Rashmi Kumari6, Princy Hira7, Shekhar Nagar3, Chandni Talwar3, Namita Nayyar8, 5 Shailly Anand9, Charu Dogra Rawat2, Mansi Verma8, Ram Krishan Negi3, Yogendra Singh3 6 and Rup Lal4* 7 8 9 10 Authors Affiliations 11 1P.G. Department of Zoology, Magadh University, Bodh Gaya, Bihar-824234, India 12 2Department of Zoology, Ramjas College, University of Delhi, New Delhi-110007, India 13 3Department of Zoology, University of Delhi, New Delhi-110007, India 14 4The Energy and Resources Institute, Darbari Seth Block, IHC Complex, Lodhi Road, New 15 Delhi-110003, India 16 5PhiXGen Private Limited, Gurugram, Haryana 122001, India 17 6Department of Zoology, College of Commerce, Arts & Science, Patliputra University, Patna, 18 Bihar-800020, India 19 7Department of Zoology, Maitreyi College, University of Delhi, New Delhi-110021, India 20 8Department of Zoology, Sri Venkateswara College, University of Delhi, New Delhi-110021, 21 India 22 9Department of Zoology, Deen Dayal Upadhyaya College, University of Delhi, New Delhi- 23 110078, India 24 25 26 27 28 *Corresponding Author 29 Email: [email protected] 30 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.006213; this version posted April 16, 2020.
    [Show full text]
  • WO 2015/149034 A2 1 October 2015 (01.10.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/149034 A2 1 October 2015 (01.10.2015) P O P C T (51) International Patent Classification: (71) Applicant: LIFE TECHNOLOGIES CORPORATION C12Q 1/68 (2006.01) [US/US]; c/o IP Legal Department Docketing, 5791 Van Allen Way, Carlsbad, California 92008 (US). (21) International Application Number: PCT/US2015/023 197 (72) Inventors: RHODES, Daniel; Life Technologies Corpora tion, c/o IP Legal Department Docketing, 579 1 Van Allen (22) International Filing Date: Way, Carlsbad, California 92008 (US). SADIS, Seth; Life 27 March 2015 (27.03.2015) Technologies Corporation, c/o IP Legal Department Dock (25) Filing Language: English eting, 5791 Van Allen Way, Carlsbad, California 92008 (US). WYNGAARD, Peter; Life Technologies Corpora (26) Publication Language: English tion, c/o IP Legal Department Docketing, 579 1 Van Allen (30) Priority Data: Way, Carlsbad, California 92008 (US). KHAZANOV, 61/971,455 27 March 2014 (27.03.2014) US Nikolay; Life Technologies Corporation, c/o IP Legal De 61/993,732 15 May 2014 (15.05.2014) US partment Docketing, 5791 Van Allen Way, Carlsbad, Cali 62/004,727 29 May 2014 (29.05.2014) us fornia 92008 (US). BANDLA, Santhoshi; Life Technolo 62/092,898 17 December 2014 (17. 12.2014) us gies Corporation, c/o IP Legal Department Docketing, 5791 Van Allen Way, Carlsbad, California 92008 (US). [Continued on nextpage] (54) Title: GENE FUSIONS AND GENE VARIANTS ASSOCIATED WITH CANCER (57) Abstract: The disclosure provides gene fusions, gene variants, and novel as RNASeq sociations with disease states, as well as kits, probes, and methods of using the (.bam) same.
    [Show full text]